Found: 32
Select item for more details and to access through your institution.
Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data.
- Published in:
- Cardiovascular Diabetology, 2018, v. 17, n. 1, p. N.PAG, doi. 10.1186/s12933-018-0759-z
- By:
- Publication type:
- Article
Once‐weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 8, p. 3020, doi. 10.1111/dom.15604
- By:
- Publication type:
- Article
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 1, p. 3, doi. 10.1111/dom.14831
- By:
- Publication type:
- Article
Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 11, p. 2199, doi. 10.1111/dom.14143
- By:
- Publication type:
- Article
The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 5, p. 779, doi. 10.1111/dom.13954
- By:
- Publication type:
- Article
Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 7, p. 1634, doi. 10.1111/dom.13708
- By:
- Publication type:
- Article
Day‐to‐day fasting self‐monitored blood glucose variability is associated with risk of hypoglycaemia in insulin‐treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 3, p. 622, doi. 10.1111/dom.13565
- By:
- Publication type:
- Article
A post‐hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla‐300) versus 100 U/mL (Gla‐100) over wider nocturnal windows in individuals with type 2 diabetes on a basal‐only insulin regimen.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 2, p. 402, doi. 10.1111/dom.13515
- By:
- Publication type:
- Article
Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice‐daily basal insulin to once‐daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 2, p. 448, doi. 10.1111/dom.13071
- By:
- Publication type:
- Article
Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 1, p. 165, doi. 10.1111/dom.13056
- By:
- Publication type:
- Article
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 10, p. 1408, doi. 10.1111/dom.12961
- By:
- Publication type:
- Article
Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2016, v. 18, n. 11, p. 1138, doi. 10.1111/dom.12702
- By:
- Publication type:
- Article
What's New in the Evolving Management of Type 2 Diabetes: Individualizing Therapy with Novel Treatment Options.
- Published in:
- Journal of Managed Care Medicine, 2018, v. 21, n. 4, p. 47
- By:
- Publication type:
- Article
Practical Considerations for Initiating and Utilizing Flash Continuous Glucose Monitoring in Clinical Practice.
- Published in:
- Journal of the Endocrine Society, 2021, v. 5, n. 9, p. 1, doi. 10.1210/jendso/bvab064
- By:
- Publication type:
- Article
Differentiating Among the SGLT-2 Inhibitors: Considering Cardiovascular and Other Safety Outcomes.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Update on Insulin Management in Type 2 Diabetes.
- Published in:
- Diabetes Spectrum, 2009, v. 22, n. 2, p. 85, doi. 10.2337/diaspect.22.2.85
- By:
- Publication type:
- Article
Practical Guidance on Effective Basal Insulin Titration for Primary Care Providers.
- Published in:
- Clinical Diabetes, 2019, v. 37, n. 4, p. 368, doi. 10.2337/cd18-0091
- By:
- Publication type:
- Article
Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial.
- Published in:
- Clinical Diabetes, 2019, v. 37, n. 1, p. 73, doi. 10.2337/cd18-0016
- By:
- Publication type:
- Article
Safety and Efficacy of Insulin Degludec/ Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications.
- Published in:
- Clinical Diabetes, 2018, v. 36, n. 2, p. 149, doi. 10.2337/cd17-0064
- By:
- Publication type:
- Article
Consensus Report: Diabetes Performance Measures: Current Status and Future Directions.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Consensus Report: Diabetes Performance Measures: Current Status and Future Directions.
- Published in:
- Clinical Diabetes, 2011, v. 29, n. 3, p. 102, doi. 10.2337/diaclin.29.3.102
- By:
- Publication type:
- Article
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 1, p. 305, doi. 10.1007/s13300-019-00735-7
- By:
- Publication type:
- Article
Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
- Published in:
- BMC Endocrine Disorders, 2017, v. 17, p. 1, doi. 10.1186/s12902-017-0180-8
- By:
- Publication type:
- Article
Circulating dendritic cell number and intracellular TNF-α production in women with type 2 diabetes.
- Published in:
- Acta Diabetologica, 2012, v. 49, p. 25, doi. 10.1007/s00592-010-0190-8
- By:
- Publication type:
- Article
Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972–1980
- Published in:
- 2017
- By:
- Publication type:
- journal article
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1).
- Published in:
- Diabetes Care, 2014, v. 37, n. 8, p. 2159, doi. 10.2337/dc13-2760
- By:
- Publication type:
- Article
Diabetes Performance Measures: Current Status and Future Directions.
- Published in:
- Diabetes Care, 2011, v. 34, n. 7, p. 1651, doi. 10.2337/dc11-0735
- By:
- Publication type:
- Article
100-OR: ADA Presidents' Select Abstract: Efficacy and Safety of Once-Weekly Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist vs. Placebo as Monotherapy in People with Type 2 Diabetes (SURPASS-1).
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-100-OR
- By:
- Publication type:
- Article
1206-P: Effects of Canagliflozin (CANA) on Initiation of Insulin in CANVAS Program.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1206-P
- By:
- Publication type:
- Article